121 related articles for article (PubMed ID: 38593510)
1. Identification of TAP1 as a T-cell related therapeutic target in gastric cancer by mediating oxalipliatin-related synergistic enhancement of immunotherapy.
Zhao Y; Liu Z; Deng K; Qu H; Zhang Q; Zhou P; Yang M; Yang X; Wang H; Li R; Xia J
Int Immunopharmacol; 2024 May; 132():111998. PubMed ID: 38593510
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy.
Tu Z; Li K; Ji Q; Huang Y; Lv S; Li J; Wu L; Huang K; Zhu X
BMC Cancer; 2023 Feb; 23(1):133. PubMed ID: 36759763
[TBL] [Abstract][Full Text] [Related]
3. TAP1, a potential immune-related prognosis biomarker with functional significance in uveal melanoma.
Zhu R; Chen YT; Wang BW; You YY; Wang XH; Xie HT; Jiang FG; Zhang MC
BMC Cancer; 2023 Feb; 23(1):146. PubMed ID: 36774490
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.
Gao J; Zhao Z; Zhang H; Huang S; Xu M; Pan H
Cancer Immunol Immunother; 2023 May; 72(5):1121-1138. PubMed ID: 36336725
[TBL] [Abstract][Full Text] [Related]
5. GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.
Zhao W; Liang Z; Yao Y; Ge Y; An G; Duan L; Yao J
Cancer Immunol Immunother; 2024 May; 73(7):131. PubMed ID: 38748299
[TBL] [Abstract][Full Text] [Related]
6. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
7. Construction of a gene model related to the prognosis of patients with gastric cancer receiving immunotherapy and exploration of COX7A1 gene function.
Wang SY; Wang YX; Shen A; Yang XQ; Liang CC; Huang RJ; Jian R; An N; Xiao YL; Wang LS; Zhao Y; Lin C; Wang CP; Yuan ZP; Yuan SQ
Eur J Med Res; 2024 Mar; 29(1):180. PubMed ID: 38494472
[TBL] [Abstract][Full Text] [Related]
8. Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data.
Li F; Li J; Yu J; Pan T; Yu B; Sang Q; Dai W; Hou J; Yan C; Zang M; Zhu Z; Su L; Li YY; Liu B
EBioMedicine; 2021 Jul; 69():103436. PubMed ID: 34157484
[TBL] [Abstract][Full Text] [Related]
9. A new risk model based on a 11-m
Lei L; Li N; Yuan P; Liu D
BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric Cancer.
Segami K; Aoyama T; Hiroshima Y; Komori K; Hashimoto I; Watanabe H; Kano K; Nagasawa S; Nakazono M; Maezawa Y; Fujikawa H; Numata M; Yamada T; Tamagawa H; Yamamoto N; Ogata T; Siozawa M; Yukawa N; Morinaga S; Rino Y; Masuda M; Miyagi Y; Saeki H; Oshima T
In Vivo; 2021; 35(5):2771-2777. PubMed ID: 34410967
[TBL] [Abstract][Full Text] [Related]
11. The DNA damage repair-related lncRNAs signature predicts the prognosis and immunotherapy response in gastric cancer.
Zhao Z; Mak TK; Shi Y; Huang H; Huo M; Zhang C
Front Immunol; 2023; 14():1117255. PubMed ID: 37457685
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.
Zhao Q; Zhang H; Li Y; Liu J; Hu X; Fan L
J Exp Clin Cancer Res; 2010 Aug; 29(1):118. PubMed ID: 20799994
[TBL] [Abstract][Full Text] [Related]
13. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
14. Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer.
Wang Q; Liang J; Hu X; Gu S; Xu Q; Yan J
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34100918
[TBL] [Abstract][Full Text] [Related]
15. New genetic insights into immunotherapy outcomes in gastric cancer via single-cell RNA sequencing and random forest model.
Yu D; Yang J; Wang B; Li Z; Wang K; Li J; Zhu C
Cancer Immunol Immunother; 2024 May; 73(6):112. PubMed ID: 38693422
[TBL] [Abstract][Full Text] [Related]
16. Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.
Zhang H; Wu J; Yuan J; Li H; Zhang Y; Wu W; Chen W; Wang C; Meng S; Chen S; Huo M; He Y; Zhang C
J Exp Clin Cancer Res; 2021 Aug; 40(1):260. PubMed ID: 34412665
[TBL] [Abstract][Full Text] [Related]
17. The Immune Subtypes and Landscape of Gastric Cancer and to Predict Based on the Whole-Slide Images Using Deep Learning.
Chen Y; Sun Z; Chen W; Liu C; Chai R; Ding J; Liu W; Feng X; Zhou J; Shen X; Huang S; Xu Z
Front Immunol; 2021; 12():685992. PubMed ID: 34262565
[TBL] [Abstract][Full Text] [Related]
18. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.
Song Z; Su M; Li X; Xie J; Han F; Yao J
BMC Gastroenterol; 2023 Dec; 23(1):432. PubMed ID: 38066437
[TBL] [Abstract][Full Text] [Related]
19. PANoptosis subtypes predict prognosis and immune efficacy in gastric cancer.
Liu Z; Sun L; Peng X; Zhu J; Wu C; Zhu W; Huang C; Zhu Z
Apoptosis; 2024 Jun; 29(5-6):799-815. PubMed ID: 38347337
[TBL] [Abstract][Full Text] [Related]
20. A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer.
Liu SJ; Yang YB; Zhou JX; Lin YJ; Pan YL; Pan JH
Dis Markers; 2021; 2021():2385406. PubMed ID: 34868391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
